Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

  • So Won Oh
  • Seung-hwan Moon
  • Do Joon Park
  • Bo Youn Cho
  • Kyeong Cheon Jung
  • Dong Soo Lee
  • June-Key Chung
Original Article
First Online:
Received:
Accepted:

Abstract

Purpose

The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with 131I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC).

Materials and methods

A total of 47 patients (13 men, 34 women; age 54.2 ± 13.6 years) with radioiodine-refractory PTC underwent therapy consisting of consecutive treatment with 131I and RA. Each 131I/RA treatment cycle involved the administration of oral isotretinoin for 6 weeks at 1–1.5 mg/kg daily followed by a single oral dose of 131I (range 5.5-16.7 GBq). Therapeutic responses were determined using serum thyroglobulin (Tg) levels and the change in tumour size 6 months after completing the 131I/RA therapy. Biological parameters and pathological parameters before and after combined therapy were compared.

Results

After completing 131I/RA therapy, 1 patient showed a complete response, 9 partial response, 9 stable disease, and 28 progressive disease, representing an overall response rate of 21.3%. Univariate analysis revealed that an age of <45 years and a persistently high serum Tg level were related to a good response. No clinical response was achieved when metastases showing no iodine uptake were present. Multivariate regression analysis showed that an age of <45 years was significantly associated with a good response. Of the 24 patients with well-differentiated carcinoma, 5 (20.8%) responded to 131I/RA therapy, whereas all 6 patients with poorly differentiated carcinoma failed to respond.

Conclusion

131I/RA therapy was found to elicit a response rate of 21.3% among patients with radioiodine-refractory PTC, and an age of <45 years was found to be significantly associated with a good response.

Keywords

Refractory papillary thyroid cancer 131I therapy Retinoic acid 
This is a preview of subscription content, log in to check access.

Notes

Conflicts of interest

None.

Reference

  1. 1.
    Goretzki PE, Simon D, Frilling A, et al. Surgical intervention for differentiated thyroid carcinoma. Br J Surg. 1994;80:1009–12.CrossRefGoogle Scholar
  2. 2.
    Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4–14.CrossRefGoogle Scholar
  4. 4.
    Hansen LA, Sigman CC, Andreola F, Rose SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2001;14:153–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997;240:832–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee YJ, Chung JK, Shin JH, Kang JH, Jeong JM, Lee DS. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid. 2004;14:889–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab. 1999;84:2249–57.CrossRefGoogle Scholar
  10. 10.
    Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metabol. 2000;85:2889–96.CrossRefGoogle Scholar
  11. 11.
    Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg. 1998;22:569–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med. 1998;39:1903–19.PubMedGoogle Scholar
  13. 13.
    Grünwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555–8.PubMedGoogle Scholar
  14. 14.
    Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;240:832–8.Google Scholar
  15. 15.
    Fernández CA, Puig-Domingo M, Lomeña F, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009;32:228–33.PubMedGoogle Scholar
  16. 16.
    Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer – final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Grünig T, Tiepolt C, Zoephel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer – does it hold its promise? Eur J Nucl Med Mol Imaging. 2003;148:395–402.Google Scholar
  18. 18.
    Courbon F, Zerdoud S, Bastie D, et al. Defective efficacy of retinoid acid treatment in patients with metastatic thyroid carcinoma. Thyroid. 2006;16:1025–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191–5.PubMedGoogle Scholar
  21. 21.
    Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf). 2002;57:215–21.CrossRefGoogle Scholar
  22. 22.
    Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74:983–6.PubMedGoogle Scholar
  23. 23.
    Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. World Health Organization: International histological classification of tumours. 2nd ed. Berlin: Springer Verlag; 1988.Google Scholar
  24. 24.
    Ahn HY, Park YJ. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med. 2009;77:537–42.Google Scholar
  25. 25.
    Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4701–4.CrossRefGoogle Scholar
  26. 26.
    Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1:162–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Teixeira C, Pratt MA. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol. 1997;11:1191–202.PubMedCrossRefGoogle Scholar
  29. 29.
    Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ. 1998;1998:11–9.CrossRefGoogle Scholar
  30. 30.
    Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16:453–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • So Won Oh
    • 1
    • 4
  • Seung-hwan Moon
    • 1
  • Do Joon Park
    • 2
  • Bo Youn Cho
    • 2
  • Kyeong Cheon Jung
    • 3
  • Dong Soo Lee
    • 1
    • 5
  • June-Key Chung
    • 1
  1. 1.Department of Nuclear MedicineSeoul National University College of MedicineSeoulRepublic of Korea
  2. 2.Department of Internal MedicineSeoul National University College of MedicineSeoulRepublic of Korea
  3. 3.Department of PathologySeoul National University College of MedicineSeoulRepublic of Korea
  4. 4.Department of Nuclear MedicineSeoul National University Boramae Medical CenterSeoulRepublic of Korea
  5. 5.Department of Molecular Medicine and Biopharmaceutical SciencesSeoul National University WCU Graduate School of Convergence Science and TechnologySeoulRepublic of Korea

Personalised recommendations